DBV Technologies Resubmits BLA for Peanut Allergy Treatment

After an eight month delay, France-based DBV Technologies announced it resubmitted a Biologics License Application to the U.S. Food and Drug Administration for its Viaskin Peanut treatment, its non-invasive allergy patch.